INS and Insulin resistance: Dipeptidyl peptidase (DPP-4) inhibitors increase incretin hormone levels, which improve insulin secretion, insulin resistance and reduce glucagon levels34,35, and they have been proven to be effective and safe in patients with T2D36–38.